Selective modulator of nuclear receptor PPARγ with reduced adipogenic potential ameliorates experimental nephrotic syndrome

Glomerular disease manifests as nephrotic syndrome (NS) with high proteinuria and comorbidities, and is frequently refractory to standard treatments. We hypothesized that a selective modulator of PPARγ, GQ-16, will provide therapeutic advantage over traditional PPARγ agonists for NS treatment. We de...

Descripción completa

Detalles Bibliográficos
Autores principales: Bryant, Claire, Rask, Galen, Waller, Amanda P., Webb, Amy, Galdino-Pitta, Marina R., Amato, Angelica A., Cianciolo, Rachel, Govindarajan, Rajgopal, Becknell, Brian, Kerlin, Bryce A., Neves, Francisco A.R., Fornoni, Alessia, Agrawal, Shipra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8927998/
https://www.ncbi.nlm.nih.gov/pubmed/35310946
http://dx.doi.org/10.1016/j.isci.2022.104001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8927998/
https://www.ncbi.nlm.nih.gov/pubmed/35310946
http://dx.doi.org/10.1016/j.isci.2022.104001

Ejemplares similares